S. Macherla

Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non–small-cell Lung Cancer

D. Costa, G. Weiss, R. Gill, 2020, Clinical Lung Cancer.

Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition

Li V. Yang, D. Liles, Justin D. McCallen, 2019, Journal of Immunotherapy for Cancer.

Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC

D. Costa, N. Rizvi, K. Kehl, 2020, JTO clinical and research reports.

A Case of Warm Autoimmune Hemolytic Anemia Secondary to Epstein-Barr Virus Infection

O. Abidoye, S. Macherla, C. Adewunmi, 2022, Cureus.

C-REACTIVE PROTEIN (CRP) AS A PROGNOSTIC BIOMARKER IN ADVANCED NON-SMALL CELL LUNG CANCER TREATED WITH IMMUNE CHECKPOINT

Brien, J. Koivunen, A. Cortellini, 2020 .

Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer

E. Zervos, S. Laks, A. Naqash, 2018, International journal of molecular sciences.

The real-world incidence of immunotherapy-related thyroid dysfunction: A retrospective analysis of a single center's experience over five years.

H. Brody, S. Macherla, C. Cherry, 2020 .